BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mukai K, Kamata M, Miyazaki M, Nagata M, Fukaya S, Hayashi K, Fukuyasu A, Ishikawa T, Ohnishi T, Tada Y, Tanaka T. Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma. J Dermatol 2021;48:707-9. [PMID: 33600004 DOI: 10.1111/1346-8138.15813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Jung T, Haist M, Kuske M, Grabbe S, Bros M. Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond. Int J Mol Sci 2021;22:9890. [PMID: 34576054 DOI: 10.3390/ijms22189890] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
2 Multiple drugs. Reactions Weekly 2021;1858:294-294. [DOI: 10.1007/s40278-021-97012-3] [Reference Citation Analysis]